US Artificial Intelligence (AI) In Genomics Market - Strategic Insights and Forecasts (2026-2031)

The US AI in Genomics Market is expected to grow at a CAGR of 33.6%, reaching USD 5,342.4 million by 2031 from USD 1,256.4 million in 2026, driven by rapid adoption of AI-driven genomic analysis tools.

Key drivers include declining whole-genome sequencing costs, exponential growth of multiomic data, federal funding for AI-biology research, and the need for faster drug discovery and precision medicine solutions.

The Drug Discovery and Development segment shows the strongest demand, as AI enables high-throughput virtual screening, causal disease mapping, and predictive modeling of compound-target interactions.

Hyperscale cloud providers and GPU vendors supply the computing backbone required for training and deploying deep learning models, making the market highly dependent on high-performance computing availability and pricing.

Competition is shifting toward companies that combine proprietary genomic data with advanced AI models, including sequencing leaders expanding into AI platforms, AI-first TechBio startups, and computing infrastructure providers supporting large-scale biological discovery.